Price
No data yet.
Social Signal Score
Analyst Ratings
11 analystsRevenue
$285.97MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Sanj K. Patel
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Employees
- 366
- Beta
- 0.08
- Country
- GB
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 17.87
Financials
Revenue
$285.97M+3612.0%Net Income
$47.34MEBITDA
$59.55MFree Cash Flow
$47.10MEPS (diluted)
$0.56Shares Outstanding (diluted)
84.92M+161.6%Operating Expenses
$98.15MCash & Debt
$568.76MReturn of Capital
$0.00Revenue by Segment (annual)
$677.56MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $677.56M | $59.01M | $0.80 |
| 2024 | $423.24M | $-43.19M | $-0.60 |
| 2023 | $270.26M | $14.08M | $0.20 |
| 2022 | $220.18M | $183.36M | $2.64 |
| 2021 | $38.54M | $-157.92M | $-2.30 |
| 2020 | $0.00 | $-161.38M | $-2.61 |
| 2019 | $0.00 | $-161.87M | $-2.99 |
| 2018 | $0.00 | $-103.23M | $-3.49 |
| 2017 | $0.00 | $-64.87M | $-2.00 |
| 2016 | $0.00 | $-23.97M | $-0.74 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $1.17
- Implied price
- $60.76
- Return from $94.23
- -8.4% a year
To earn 15.0% a year on these assumptions you'd need to buy at $30.21 — -67.9% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 36 | 44 | 52 | 60 | 68 |
|---|---|---|---|---|---|
| -2.0% | -22.8% | -19.6% | -16.9% | -14.5% | -12.3% |
| 3.0% | -18.8% | -15.5% | -12.6% | -10.1% | -7.8% |
| 8.0% | -14.9% | -11.4% | -8.4% | -5.7% | -3.4% |
| 13.0% | -11.0% | -7.3% | -4.2% | -1.4% | 1.1% |
| 18.0% | -7.0% | -3.2% | 0.1% | 3.0% | 5.6% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
65+30.00%Social Signal Score
Mentions (9)
- Newszacks.com·2d ago·Positive
Why Kiniksa Pharmaceuticals International, plc (KNSA) is a Top Momentum Stock for the Long-Term Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
View source ↗ - Newszacks.com·18d ago·Positive
Here's Why Kiniksa Pharmaceuticals International, plc (KNSA) is a Strong Momentum Stock Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
View source ↗ - Newsfool.com·26d ago·Positive
Kiniksa Pharmaceuticals: 3 Key Takeaways for Long-Term Investors Kiniksa raised 2026 revenue guidance to over $1.045 billion. ARCALYST penetration among multiple recurrence patients reached 23%.
View source ↗ - Newsmarketbeat.com·26d ago·Negative
What Kiniksa Pharmaceuticals International (KNSA) Said on Its Q3 Earnings Call Kiniksa Pharmaceuticals International NASDAQ: KNSA raised its full-year 2026 revenue guidance after reporting third-quarter ARCALYST revenue growth of 58% year over year, as the company continued to expand use of the drug for recurrent pericarditis and advance its clinical pipeline.
View source ↗ - Newsseekingalpha.com·26d ago·Positive
Kiniksa Pharmaceuticals International, plc (KNSA) Q3 2026 Earnings Call Transcript Kiniksa Pharmaceuticals International, plc (KNSA) Q3 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·26d ago·Positive
Kiniksa Pharmaceuticals International, plc (KNSA) Q3 Earnings and Revenues Surpass Estimates Kiniksa Pharmaceuticals International, plc (KNSA) came out with quarterly earnings of $0.56 per share, beating the Zacks Consensus Estimate of $0.32 per share. This compares to earnings of $0.23 per share a year ago.
View source ↗ - Newsglobenewswire.com·26d ago·Neutral
…H 2027 – – Conference call and webcast scheduled for 8:30 am ET today – LONDON, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications, today reported third quarter 2026 financial results and recent portfolio execution. “Kiniksa continues to build a leading IL-1α and IL-1β inhibition franchise, driven b…
View source ↗ - Newszacks.com·66d ago·Neutral
Kiniksa Pharmaceuticals Stock Rallies 41% in Three Months: Here's Why KNSA is gaining momentum as Arcalyst sales surge and pipeline advances strengthen prospects for continued growth.
View source ↗ - Newsglobenewswire.com·79d ago·Neutral
Kiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare Conference LONDON, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026 at 8:45 a.m. Eastern Time.
View source ↗
Earnings
Tue, Feb 23(in 3 months)
Consensus estimate $0.25 per share
Typical surprise +27.8% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Oct 27$0.56 vs $0.37beat
- Tue, Jul 28$0.30 vs $0.30beat
- Tue, Apr 28$0.27 vs $0.18beat
- Tue, Feb 24$0.17 vs $0.29miss
- Tue, Oct 28$0.23 vs $0.33miss
- Tue, Jul 29$0.23 vs $0.18beat
Estimates and results for KNSA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by KNSA officers and directors.
- Bought
- —
- Sold
- $77.2m
0 trades
50 trades
- Megna Michael Rsold
- Patel Sanj Ksold
- Patel Sanj Ksold
- Patel Sanj Ksold
- Patel Sanj Ksold
- Patel Sanj Ksold
- Patel Sanj Ksold
- Patel Sanj Ksold
50 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in KNSA.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
